Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GRNA-seq from Ishikawa after medroxyprogesterone treatment

ABSTRACT: gRNA-seq from Ishikawa after medroxyprogesterone treatment

PROVIDER: PRJNA1006344 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25663219_1.fastq.gz	Fastqsanger.gz
	SRR25663219_2.fastq.gz	Fastqsanger.gz
	SRR25663220_1.fastq.gz	Fastqsanger.gz
	SRR25663220_2.fastq.gz	Fastqsanger.gz
	SRR25663221_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

gRNA-seq from Ishikawa after medroxyprogesterone treatment

Project description:Hormone therapy serves as a primary choice for fertility preservation and is also considered for advanced and recurrent cases with endometrial cancer. While a number of patients fail to respond favorably to hormone treatments. In order to explore the mechanisms underpinning hormone resistance, Here we constructed a whole-genome library for EAC cell lines using the CRISPR-Cas9 system and performed high-throughput sequencing after medroxyprogesterone treatment in this study. For CRISPR screening, ishikawa cells were infected pooled GeCkov2 lentiviral library with functional MOI of 0.3. Genomic DNA from each group was isolated and amplified by PCR. The PCR products were purified and subjected to NGS by using the Novaseq 6000-PE150 platform. After 48h of puromycin selection, the cells were divided into three groups, the baseline group cells were collected and frozen at -80 degree centigrade, the control group cells were treated with DMSO for 10 days while the MPA group cells were treated with 15 μM MPA for 10 days.

2024-02-12 | GSE241070 | GEO

RNA Sequencing of Ishikawa Cell Line with NCF2 Knockdown Using Small Interfering RNA

Project description:Progestin therapy is one of the preferred treatment modalities for early-stage endometrial cancer patients wishing to retain fertility and for conservatively managing advanced endometrial cancer. However, a significant number of patients currently do not benefit from progestin therapy due to issues such as progestin resistance. In the past, we established a medroxyprogesterone acetate-resistant Ishikawa cell line. From this, we identified the NCF2 gene, which was highly expressed in the resistant group. Functional validation experiments revealed that knocking down NCF2 can effectively reverse progestin resistance. To explore its mechanism, we performed RNA sequencing post-NCF2 knockdown.

2024-06-30 | GSE242226 | GEO

Analysis of gene expression change between Ishikawa-02 SC and Ishikawa-02 shSOX2

Project description:We collected total RNA from both Ishikawa-02 SC and Ishikawa-02 shSOX2 and examined mRNA expression profile, comprehensively.

2018-05-18 | GSE114582 | GEO

Cas9 gRNA engineering for selectable genome editing, activation and repression

Project description:RNA-Seq after Cas9-gRNA transfection with different length gRNAs we performed PolyA Selection and RNA-Seq on cells transfected with dCas9-VPR and a gRNA of each length (20nt, 16nt, or 14nt) targeting ACTC1, MIAT, or HBG1/2

2015-07-15 | E-GEOD-70694 | biostudies-arrayexpress

polyA mRNA RNA-seq from Ishikawa (ENCSR000BYA)

Project description:RNA-seq on ECC-1 greater than 200bp polyA+ treated with dimethylsulfoxide for 4 hours. Note- This experiment previously referred to its biosample as ECC-1, however it has been found that all currently available ECC-1 are actually Ishikawa cells. For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2017-02-03 | GSE93438 | GEO

polyA mRNA RNA-seq from Ishikawa (ENCSR000BYC)

Project description:RNA-seq on ECC-1 greater than 200bp polyA+ treated with genistein at 100nM for 4 hours. Note- This experiment previously referred to its biosample as ECC-1, however it has been found that all currently available ECC-1 are actually Ishikawa cells. For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2017-02-03 | GSE93440 | GEO

polyA mRNA RNA-seq from Ishikawa (ENCSR000BYB)

Project description:RNA-seq on ECC-1 greater than 200bp polyA+ treated with estradiol at 10nM for 4 hours. Note- This experiment previously referred to its biosample as ECC-1, however it has been found that all currently available ECC-1 are actually Ishikawa cells. For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2017-02-03 | GSE93439 | GEO

polyA mRNA RNA-seq from Ishikawa (ENCSR000BXZ)

Project description:RNA-seq on ECC-1 greater than 200bp polyA+ treated with bisphenol A at 100nM for 4 hours. Note- This experiment previously referred to its biosample as ECC-1, however it has been found that all currently available ECC-1 are actually Ishikawa cells. For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2017-02-03 | GSE93437 | GEO

RNASeq of Arg2 gRNA or scrambled gRNA CRISPR'd Tregs

Project description:RNASeq of Arg2 gRNA or scrambled gRNA CRISPR'd Tregs

| PRJNA588065 | ENA

ARID1A and the BAF complex are determinants of breast cancer treatment response [CRISPR gRNA-seq]

Project description:ARID1A and the BAF complex are determinants of breast cancer treatment response [CRISPR gRNA-seq]

| PRJNA508099 | ENA